Cargando…
Chapter 8 Paramyxoviruses
The paramyxoviruses are a heterogeneous group of viruses causing a variety of clinical diseases in humans, animals, and birds. This chapter examines in more detail the structure and properties of the important human viruses in this group, namely measles, respiratory syncytial virus (RSV), mumps and...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
1985
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172905/ https://www.ncbi.nlm.nih.gov/pubmed/32336840 http://dx.doi.org/10.1016/S0168-7069(08)70016-8 |
_version_ | 1783524349284712448 |
---|---|
collection | PubMed |
description | The paramyxoviruses are a heterogeneous group of viruses causing a variety of clinical diseases in humans, animals, and birds. This chapter examines in more detail the structure and properties of the important human viruses in this group, namely measles, respiratory syncytial virus (RSV), mumps and parainfluenza viruses I-V. They are all enveloped, negative-stranded, riboviruses of helical symmetry. It is suggested that susceptible children, adolescents, and adults should be vaccinated against mumps, unless vaccination is contraindicated. Mumps vaccine can be of particular value to children approaching puberty and for adolescents and adults, especially males who have not had mumps in childhood. Ribavirin therapy may be particularly beneficial for children at risk for severe and often fatal RSV infection, such as infants with congenital heart disease. Attenuated measles vaccines have been developed empirically by selection of host range mutants, and are widely and successfully used throughout the world. Using the vaccine, some countries may soon eliminate measles as an endogenous virus but continued problems are anticipated, particularly in adults with viruses re-introduced by visitors from abroad. Basic studies on new antivirals are continuing (particularly with oligopeptides) but antiviral compounds are unlikely to have extended use in the clinic, except perhaps in tropical areas where the disease may be life threatening. However, a vaccination programme in these areas is preferable, and is an urgent need. |
format | Online Article Text |
id | pubmed-7172905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1985 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71729052020-04-22 Chapter 8 Paramyxoviruses Perspect Med Virol Article The paramyxoviruses are a heterogeneous group of viruses causing a variety of clinical diseases in humans, animals, and birds. This chapter examines in more detail the structure and properties of the important human viruses in this group, namely measles, respiratory syncytial virus (RSV), mumps and parainfluenza viruses I-V. They are all enveloped, negative-stranded, riboviruses of helical symmetry. It is suggested that susceptible children, adolescents, and adults should be vaccinated against mumps, unless vaccination is contraindicated. Mumps vaccine can be of particular value to children approaching puberty and for adolescents and adults, especially males who have not had mumps in childhood. Ribavirin therapy may be particularly beneficial for children at risk for severe and often fatal RSV infection, such as infants with congenital heart disease. Attenuated measles vaccines have been developed empirically by selection of host range mutants, and are widely and successfully used throughout the world. Using the vaccine, some countries may soon eliminate measles as an endogenous virus but continued problems are anticipated, particularly in adults with viruses re-introduced by visitors from abroad. Basic studies on new antivirals are continuing (particularly with oligopeptides) but antiviral compounds are unlikely to have extended use in the clinic, except perhaps in tropical areas where the disease may be life threatening. However, a vaccination programme in these areas is preferable, and is an urgent need. Published by Elsevier B.V. 1985 2008-05-29 /pmc/articles/PMC7172905/ /pubmed/32336840 http://dx.doi.org/10.1016/S0168-7069(08)70016-8 Text en © 1985 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Chapter 8 Paramyxoviruses |
title | Chapter 8 Paramyxoviruses |
title_full | Chapter 8 Paramyxoviruses |
title_fullStr | Chapter 8 Paramyxoviruses |
title_full_unstemmed | Chapter 8 Paramyxoviruses |
title_short | Chapter 8 Paramyxoviruses |
title_sort | chapter 8 paramyxoviruses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172905/ https://www.ncbi.nlm.nih.gov/pubmed/32336840 http://dx.doi.org/10.1016/S0168-7069(08)70016-8 |